OTCMKTS:SHEZF Shenzhen Hepalink Pharmaceutical Group (SHEZF) Stock Price, News & Analysis $0.47 +0.02 (+4.52%) As of 05/29/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Shenzhen Hepalink Pharmaceutical Group Stock (OTCMKTS:SHEZF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SHEZF alerts:Sign Up Key Stats Today's Range$0.42▼$0.4750-Day Range$0.47▼$0.4752-Week Range$0.47▼$0.47VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E Ratio6.79Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company specializing in the research, development, manufacturing and sale of heparin and related products. The company’s core product line centers on heparin sodium APIs (active pharmaceutical ingredients), low-molecular-weight heparins (LMWH) and specialty heparin derivatives. In addition to bulk heparin APIs, Hepalink produces a range of finished dosage forms such as heparin injections and protamine sulfate, serving hospitals, distributors and pharmaceutical companies. Since its founding in the late 1990s in Shenzhen, Hepalink has grown to become one of the world’s leading suppliers of heparin and LMWH. The company operates multiple GMP-certified manufacturing facilities in China and holds regulatory approvals from major markets, including China’s NMPA, the U.S. FDA and the European Medicines Agency. Hepalink exports its products to more than 80 countries and regions, with significant markets in North America, Europe, Asia and Latin America, where it supports both generic and specialty anticoagulant therapies. Beyond heparin APIs and formulations, Hepalink has expanded its R&D capabilities to include recombinant proteins, monoclonal antibodies and other biologics. The company collaborates with academic institutions and international partners to advance novel drug candidates and optimize production processes. With a focus on quality control, regulatory compliance and innovation, Shenzhen Hepalink continues to invest in research facilities and process development to support long-term growth in both domestic and global pharmaceutical markets.AI Generated. May Contain Errors. Read More Receive SHEZF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shenzhen Hepalink Pharmaceutical Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SHEZF Stock News HeadlinesShenzhen Hepalink Sets Final 2025 Dividend and Updated Payment DateMay 26, 2026 | tipranks.comShenzhen Hepalink Sets Final 2025 Dividend and Details Withholding Tax RulesMay 22, 2026 | tipranks.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.May 30 at 1:00 AM | Behind the Markets (Ad)Shenzhen Hepalink Details Board Composition and Committee RolesMay 22, 2026 | tipranks.comHepalink Shareholders Back All Resolutions at 2025 AGMMay 22, 2026 | tipranks.comHepalink Pharma Names New Employee Representative Director as Board Term RenewsMay 22, 2026 | tipranks.comHepalink Files Unaudited First-Quarter 2026 Report With Full Board ApprovalApril 29, 2026 | tipranks.comShenzhen Hepalink Sets Board Meeting to Approve Q1 2026 ResultsApril 17, 2026 | tipranks.comSee More Headlines SHEZF Stock Analysis - Frequently Asked Questions How have SHEZF shares performed this year? Shenzhen Hepalink Pharmaceutical Group's stock was trading at $0.4696 at the beginning of 2026. Since then, SHEZF stock has increased by 0.0% and is now trading at $0.4696. How do I buy shares of Shenzhen Hepalink Pharmaceutical Group? Shares of SHEZF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:SHEZF CIKN/A Webwww.hepalink.com Phone86-755-2698-0200FaxN/AEmployees2,080Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio6.79 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:SHEZF) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shenzhen Hepalink Pharmaceutical Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.